Citius Pharmaceuticals (CTXR) Expected to Announce Quarterly Earnings on Wednesday

Citius Pharmaceuticals (NASDAQ:CTXR) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of $0.3885 per share and revenue of $18.79 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earnings data on Friday, February 13th. The company reported ($0.38) earnings per share for the quarter.

Citius Pharmaceuticals Trading Down 3.3%

Shares of NASDAQ CTXR opened at $0.69 on Wednesday. The firm has a market capitalization of $15.38 million, a price-to-earnings ratio of -0.28 and a beta of 1.05. Citius Pharmaceuticals has a one year low of $0.57 and a one year high of $2.48. The business has a fifty day simple moving average of $0.80 and a 200 day simple moving average of $0.97.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several large investors have recently made changes to their positions in the company. XTX Topco Ltd lifted its holdings in Citius Pharmaceuticals by 572.8% during the 4th quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock valued at $83,000 after purchasing an additional 91,196 shares during the last quarter. Heights Capital Management Inc. acquired a new stake in shares of Citius Pharmaceuticals during the fourth quarter worth approximately $622,000. Asset Advisory Group Inc. acquired a new stake in shares of Citius Pharmaceuticals during the fourth quarter worth approximately $46,000. Finally, NewEdge Advisors LLC bought a new position in shares of Citius Pharmaceuticals in the second quarter valued at approximately $40,000. Institutional investors own 16.88% of the company’s stock.

Analyst Upgrades and Downgrades

CTXR has been the subject of a number of analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Citius Pharmaceuticals in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Friday, March 27th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.00.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical?stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital?acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter?related bloodstream infections without catheter removal.